MNT: Weight Management (2015)
Jensen GL, Roy M, Buchanan AE, Berg MB. Weight loss intervention for obese older women: I mprovements in performance and function. Obes Res. 2004; 12(11): 1,814-1,820.
PubMed ID: 15601977- Anthropometrics
- Laboratory results
- Physical performance
- Functionality
- Quality of life.
- At 60 years of age or more
- At 30kg/m2 or more
- Community dwelling
- Ambulatory
- Having a phone
- Expected to live 12 months or more
- Signed informed consent.
Recruitment
Local print, electronic and TV advertisements used to recruit subjects in Nashville, TN.
Design
- Pre- intervention and post-intervention
- No control group.
Intervention
- Free three-month weight loss program consisting of a prudent diet, behavior modification and physical activity. A baseline and follow-up assessment were conducted by a bariatric physician and eight counseling sessions were provided by a dietitian (30 minutes each) between baseline and completion of the program. Participants were encouraged to:
- Reduce caloric intake to 1,200kcal to 1,500kcal per day
- Take multi-vitamins with minerals and calcium and vitamin D supplements
- Consume two to three servings of calcium-rich foods per day
- Consume foods high in B12 and folic acid
- Keep a food diary for duration of study
- Keep an activity diary (steps per day) for the duration, with a target of 5,000 steps per day.
- A dietitian reviewed food and activity diaries with each participant at each visit and developed new goals based on reports from the diaries. Weight loss goal was a 5% reduction in weight. All education materials were available in large font, with an eight-grade reading level.
Statistical Analysis
- Descriptive statistics for continuous and categorical data
- A Wilcoxon Signed Rank test was used to compare continuous pre-outcome and post-outcome measures
- A McNemar test was used to compare change in paired categorical outcome measures.
Timing of Measurements
Assessments were completed at baseline and the three-month follow-up visit. They included- Laboratory:
- Lipid panel
- FBG
- HbA1C.
- Anthropometric:
- Height
- Weight
- Fat mass or fat-free mass via BIA.
- Functional: Seven performance measures
- Quality-of-life assessments:
- SF-36
- Life Space Assessment (LSA).
Dependent Variables
- Weight: Reported in kg; taken on a digital scale without over-garments or shoes
- Height: Wall-mounted stadiometer
- Lipid panel:
- Total cholesterol
- LDL-C
- HDL-C
- TG.
- Body composition: Bioelectrical impedance (BIA) was used to estimate fat and fat-free mass
- Physical performance: Seven tests were used and scored on a four-point scale (range zero to 28), with a high score being a better performance
- Step counts: Pedometer
- Health status:
- Short-Form 36 Health Status Survey (SF-36): Measures eight domains
- Life Space Assessment (LSA): Provides assessment of mobility and functioning.
Independent Variables
The three-month intervention.
Control Variables
Dietary intake was assessed by the dietitian within two weeks of baseline assessment using three non-consecutive 24-hour recalls obtained via phone. The multiple-pass approach was used and visual aids were given to participants. NDS-R was used for analysis. The three recalls were averaged and used to assess adequacy of baseline nutrient intake compared to the DRI.
- Initial N: A total of 26 females
- Attrition (final N): A total of 18 (31% attrition). There were no statistically significant differences at baseline between study completers and those who withdrew except for the number of medications taken [completers 7.5 (SD 3.1) and non-completers = 6.9 (SD 6.9)]
- Age: Mean (SD) = 64.1 years (4.8)
- Ethnicity:
- Non-Hispanic white: A total of 16/18 (89%)
- African American: A total of 2/18 (11%).
- Other relevant demographics:
- Education level: High school or more
- Mean number of co-morbidities at baseline: 3.2 (1.3)
- Mean caloric intake = 1,785kcal (467)
- All DRIs were met except for fiber and vitamin D.
- Anthropometrics: Mean baseline BMI of 39.1kg/m2 (6.6 kg/m2)
- Location: Nashville, TN.
Measure | Baseline | Three-month Follow-up | P-value |
Weight, kg (SD) | 100.4 (15.5) | 96.1 (17.8) | 0.006 |
BMI, kg/m2 (SD) | 39.1 (6.6) | 37.6 (7.7) | 0.008 |
FFM, kg (SD) | 46.6 (3.4) | 45.3 (4.5) | 0.019 |
FM, kg (SD) | 54.2 (13.1) | 51.1 (14.0) | 0.015 |
Systolic blood pressure, mm Hg (SD) | 130.6 (15.8) | 126.0 (8.9) | 0.306 |
Diastolic blood pressure, mm Hg (SD) | 84.4 (6.5) | 78.9 (6.2) | 0.043 |
Total cholesterol, mg per dL (SD) | 204.6 (33.2) | 192.5 (38.3) | 0.042 |
HDL-C, mg per dL (SD) | 65.0 (17.0) | 61.8 (14.4) | 0.422 |
LDL-C, mg per dL (SD) | 112.5 (30.6) | 107.2 (40.5) | 0.308 |
TG, mg per dL (SD) | 136.4 (51.5) | 124.1 (59.2) | 0.026 |
Step count, mean (SD) | 4,027 (2515) | 5,883 (3214) | 0.015 |
Physical performance score, mean (SD) | 21.6 (4.5) | 22.7 (4.2) | 0.026 |
SF-36 general health, mean (SD) | 62.2 (17.8) | 67.8 (19.3) | 0.119 |
LSA Independent life space, N (%) | 14.9 (77.8) | 15 (83.3) | 1.0 |
- Selection bias
- Lack of control group
- More than 30% withdrawal
- An inability to generalize findings.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | No | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | No | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | No | |
2.2. | Were criteria applied equally to all study groups? | N/A | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | No | |
3. | Were study groups comparable? | N/A | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | N/A | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | N/A | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | No | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | No | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | No | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | N/A | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | No | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | No | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | No | |
6.6. | Were extra or unplanned treatments described? | No | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | No | |
7.7. | Were the measurements conducted consistently across groups? | N/A | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | N/A | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | No | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |